Naloxone As an Adjuvant To Fenanyl-Bupivacaine in Thoracic Paravertebral Block Analgesia

Role Of ultra-low dose of naloxone As an Adjuvant To Fenanyl-Bupivacaine in Thoracic Paravertebral Block Analgesia after modified radical mastectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201709002599279

Enrollment

135

Registered

2017-09-08

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Surgery Thoracic Paravertebral Block Analgesia after modified radical mastectomy

Interventions

bupavacaine group

fentanyl group

naloxon group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 135 patients, ASA I &II, age 40-60 years, from both sex scheduled to undergoing unilateral modified radical mastectomy

Exclusion criteria

Exclusion criteria: ¿ Patients with known allergy to amide type local anesthetics ¿ Patients receiving non-steroidal anti-inflammatory drugs ¿ Schizophrenia or other psychotic disorder or cognitive impairment ¿ History of drug dependency or substance addiction ¿ BMI 30 kg m2 ¿ coagulation disorders ¿ local skin infection at the side of injection, spinal metastasis

Design outcomes

Primary

Measure	Time frame
postoperative pain	—

Secondary

Measure	Time frame
Depth of anaesthesia	—

Countries

Egypt

Contacts

Public Contactnada omara

Dr.nada.emera@gmail.com01118342012

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026